Skip to content


  • Meeting abstract
  • Open Access

HTLV-1 associated myelopathy of rapid onset and progression following living-donor kidney transplant: Clinical description and initial response to empirical treatment

  • 1Email author,
  • 2,
  • 1,
  • 1,
  • 2,
  • 2,
  • 3, 4 and
  • 3, 4
Retrovirology20118 (Suppl 1) :A56

  • Published:


  • Tacrolimus
  • Lamivudine
  • Zidovudine
  • Baclofen
  • Empirical Treatment

Objective and methods

To describe a case of HTLV-1 associated myelopathy (HAM/TSP) of rapid onset and progression in a renal transplant recipient, and the initial response to empirical treatment.


A 50-year-old man was admitted with 12 weeks of evolving spastic paraparesis and urinary–fecal retention, five months after a successful living-donor renal transplantation due to end-stage chronic kidney disease. He was on basiliximab, metilprednisolone, tacrolimus, mychophenolate and prednisone for immunosupression.

The physical examination showed pyramidal syndrome predominantly in lower limbs, with hyperalgesia and hypersthesia. The Kurtzke's Expanded Disability Scale (EDSS) showed a score of 7.5. Magnetic resonance imaging showed enlargement and inflammatory pattern in whole spinal cord. HTLV-1 ELISA was positive both in fresh blood and cerebrospinal fluid (CSF). HTLV-1 proviral load by Sybr-Green quantitative real-time PCR performed twice were 1879 copies/10,000 peripheral blood lymphocytes, and 6465 copies/10,000 CSF lymphocytes. Although HTLV-1 screening had not been performed before transplantation neither in the donor nor in the recipient, results were positive in a fresh blood sample from the donor, and negative in one from the recipient cryopreserved two years before transplantation.

The patient received empirical treatment with a pulse of corticosteroids, zidovudine, lamivudine, prednisone and baclofen. After one month of treatment, the EDSS showed a score of 7.

Conclusion and interpretations

This case report shows a very acute clinical presentation of HAM/TSP with extensive and diffuse spinal cord involvement in an immunosuppressed patient. In endemic areas, HTLV-1 screening should be included in protocols of organs’ donors and recipients before transplantation.

Authors’ Affiliations

Departamento de Trasplante Renal, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Perú
Instituto de Medicina Tropical “Alexander von Humboldt”, Universidad Peruana Cayetano Heredia, Lima, Perú
Instituto de Medicina Tropical “Alexander von Humboldt”, Universidad Peruana Cayetano Heredia, Lima, Perú
Departamento de Enfermedades Infecciosas, Tropicales y Dermatológicas, Hospital Nacional Cayetano Heredia, Lima, Perú


© Gonzales et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.